Clinical-stage biotechnology company developing cell-free extracellular vesicle therapies derived from mesenchymal stem cells
Clinical-stage biotechnology company developing cell-free extracellular vesicle therapies derived from mesenchymal stem cells. Its lead candidate, AGLE-102, is being studied for recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder, with potential applications in wound healing and other dermatological, immunological, and protein-deficiency disorders.